Châtillon, France, September 4, 2024 (22:30 CET)
DBV Technologies to Participate in 26th Annual HC Wainwright Global Investment Conference
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, will participate in a “Fireside Chat” at the 26th Annual HC Wainwright Global Investment Conference on Monday, September 9, 2024, at 3:00 p.m. ET in New York City.
A live webcast of the presentation can be accessed here and will also be available on the “Events” page of the “Investors” section of the Company’s website: https://dbv-technologies.com/en/investor-overview/events/
A replay will also be available for 90 days after the event.
About DBV Technologies
DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatment options for food allergies and other immunological conditions with significant unmet medical needs. DBV Technologies is currently focused on investigating the use of its proprietary technology, the VIASKIN® patch, to treat food allergies caused by a hypersensitive immune response and characterized by a range of symptoms ranging in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through EPIT® epicutaneous immunotherapy, the VIASKIN® patch is designed to deliver microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by retraining the immune system to desensitize to the allergen by leveraging the immune tolerance properties of the skin. DBV Technologies is committed to transforming the treatment of people with food allergies. The Company’s food allergy programs include ongoing clinical studies with the VIASKIN® peanut patch in young children (ages 1 to 3 years) and children (ages 4 to 7 years) with peanut allergy.
Read more
DBV Technologies’ global headquarters are located in Châtillon, France, with North American operations based in Warren, New Jersey. The Company’s ordinary shares are traded on Segment B of Euronext Paris (symbol: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing one ordinary share) are traded on the Nasdaq Stock Market (symbol: DBVT—CUSIP: 23306J101).
For more information, please visit www.dbv-technologies.com and connect with us on X (formerly Twitter) and LinkedIn.
Contact with investors
Katie Matthews
DBV Technologies
[email protected]
Media Contact
Angela Marcucci
DBV Technologies
[email protected]
VIASKIN® and EPIT® are registered trademarks of DBV Technologies.
Attachment
